company background image
BMEA

Biomea Fusion NasdaqGS:BMEA Stock Report

Last Price

US$12.03

Market Cap

US$350.9m

7D

37.5%

1Y

-20.2%

Updated

27 Jun, 2022

Data

Company Financials +
BMEA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

BMEA Stock Overview

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases.

Biomea Fusion Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biomea Fusion
Historical stock prices
Current Share PriceUS$12.03
52 Week HighUS$16.28
52 Week LowUS$2.84
Beta0
1 Month Change107.06%
3 Month Change169.73%
1 Year Change-20.23%
3 Year Changen/a
5 Year Changen/a
Change since IPO-35.32%

Recent News & Updates

Shareholder Returns

BMEAUS BiotechsUS Market
7D37.5%10.3%6.3%
1Y-20.2%-24.5%-18.8%

Return vs Industry: BMEA exceeded the US Biotechs industry which returned -24.3% over the past year.

Return vs Market: BMEA underperformed the US Market which returned -18.4% over the past year.

Price Volatility

Is BMEA's price volatile compared to industry and market?
BMEA volatility
BMEA Average Weekly Movement20.8%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: BMEA is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 21% a week.

Volatility Over Time: BMEA's weekly volatility has increased from 15% to 21% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201757Thomas Butlerhttps://biomeafusion.com

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Biomea Fusion Fundamentals Summary

How do Biomea Fusion's earnings and revenue compare to its market cap?
BMEA fundamental statistics
Market CapUS$350.90m
Earnings (TTM)-US$52.08m
Revenue (TTM)n/a

0.0x

P/S Ratio

-6.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BMEA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$52.08m
Earnings-US$52.08m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.79
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did BMEA perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is BMEA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BMEA?

Other financial metrics that can be useful for relative valuation.

BMEA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-3.6x
PEG Ration/a

Price to Book Ratio vs Peers

How does BMEA's PB Ratio compare to its peers?

BMEA PB Ratio vs Peers
The above table shows the PB ratio for BMEA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average4.4x
HRTX Heron Therapeutics
14x59.2%US$336.1m
ICVX Icosavax
1.4x-2.4%US$355.6m
CCCC C4 Therapeutics
1x-20.7%US$354.8m
DYN Dyne Therapeutics
1.1x-19.0%US$362.0m
BMEA Biomea Fusion
2.1x-2.9%US$350.9m

Price-To-Book vs Peers: BMEA is good value based on its Price-To-Book Ratio (2.1x) compared to the peer average (4.4x).


Price to Earnings Ratio vs Industry

How does BMEA's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: BMEA is expensive based on its Price-To-Book Ratio (2.1x) compared to the US Biotechs industry average (1.6x)


Price to Book Ratio vs Fair Ratio

What is BMEA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BMEA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate BMEA's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of BMEA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BMEA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BMEA's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BMEA's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Biomea Fusion forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-2.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BMEA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BMEA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BMEA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BMEA is forecast to have no revenue next year.

High Growth Revenue: BMEA is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BMEA's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Biomea Fusion performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-383.2%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: BMEA is currently unprofitable.

Growing Profit Margin: BMEA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if BMEA's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare BMEA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BMEA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: BMEA has a negative Return on Equity (-31.61%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Biomea Fusion's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BMEA's short term assets ($167.0M) exceed its short term liabilities ($8.0M).

Long Term Liabilities: BMEA's short term assets ($167.0M) exceed its long term liabilities ($2.1M).


Debt to Equity History and Analysis

Debt Level: BMEA is debt free.

Reducing Debt: BMEA had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BMEA has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: BMEA has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 102.2% each year.


Discover healthy companies

Dividend

What is Biomea Fusion current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BMEA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BMEA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BMEA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BMEA's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BMEA has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Thomas Butler (40 yo)

4.83yrs

Tenure

US$6,661,207

Compensation

Mr. Thomas Butler co-founded Biomea Fusion, Inc in August 2017 and has been its Chief Executive Officer and Director since August 2017. He serves as the Chairman of Biomea Fusion, Inc. He serves as a Manag...


CEO Compensation Analysis

Compensation vs Market: Thomas's total compensation ($USD6.66M) is above average for companies of similar size in the US market ($USD2.83M).

Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: BMEA's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

Experienced Board: BMEA's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Biomea Fusion, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Biomea Fusion, Inc.
  • Ticker: BMEA
  • Exchange: NasdaqGS
  • Founded: 2017
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$350.899m
  • Shares outstanding: 29.17m
  • Website: https://biomeafusion.com

Number of Employees


Location

  • Biomea Fusion, Inc.
  • 900 Middlefield Road
  • 4th Floor
  • Redwood City
  • California
  • 94063
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/27 00:00
End of Day Share Price2022/06/27 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.